Dec 18 (Reuters) - Albireo Pharma Inc ::ALBIREO GRANTED ORPHAN DESIGNATION BY EUROPEAN COMMISSION FOR LEAD PRODUCT CANDIDATE A4250 FOR TREATMENT OF BILIARY ATRESIA.ALBIREO PHARMA - PLAN TO EXPAND DEVELOPMENT OF A4250 IN RARE CHOLESTATIC LIVER DISEASES IN 2019.ALBIREO PHARMA - ORPHAN DESIGNATION PROVIDES 10 YEARS MARKET EXCLUSIVITY UPON APPROVAL PLUS 2 YEARS UPON COMPLETION OF PEDIATRIC INVESTIGATION PLAN.
Full Article
Nov 13 (Reuters) - Albireo Pharma Inc ::ALBIREO REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.17.Q3 REVENUE $237,000.Q3 REVENUE VIEW $892,000 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.98 -- THOMSON REUTERS I/B/E/S.ODEVIXIBAT SELECTED AS INTERNATIONAL NONPROPRIETARY NAME (INN) FOR A4250.A4250 GRANTED FAST TRACK AND ADDITIONAL ORPHAN DRUG DESIGNATIONS.A4250 PHASE 3 TRIAL PROGRESSING AS PLANNED, NEW NATURAL HISTORY DATA PRESENTED AT AASLD.ALBIREO PHARMA - HAD CASH AND CASH EQUIVALENTS AT SEPT 30, 2018 OF $173.6 MILLION, COMPARED TO $53.2 MILLION AT DEC 31, 2017.ALBIREO PHARMA - EXPECT CURRENT CASH BALANCE TO BE SUFFICIENT TO MEET OPERATING NEEDS INTO 2021.ALBIREO PHARMA - FOR FY 2018, ANTICIPATE TOTAL EXPENSES, INCLUDING RESEARCH AND DEVELOPMENT AND G&A EXPENSES, TO BE AT HIGH END OF RANGE OF $45 MILLION -$50 MILLION.
Full Article
Jan 19 (Reuters) - Albireo Pharma Inc ::ALBIREO TO RECEIVE MORE THAN $55 MILLION(1) IN NONDILUTIVE CASH PAYMENTS.ALBIREO PHARMA INC - ELOBIXIBAT APPROVED IN JAPAN FOR TREATMENT OF CHRONIC CONSTIPATION.ALBIREO PHARMA - JAPAN'S MINISTRY OF HEALTH, LABOR & WELFARE APPROVED NEW DRUG APPLICATION FOR ELOBIXIBAT FOR TREATMENT OF CHRONIC CONSTIPATION IN JAPAN.ALBIREO PHARMA INC - APPROVAL OF ELOBIXIBAT IN JAPAN TRIGGERS PAYMENTS TO ALBIREO SUBSIDIARY ELOBIX AB FROM EA PHARMA CO LTD.ALBIREO PHARMA - CO EXPECTS TO INITIATE A PLANNED PHASE 3 STUDY OF A4250 BY SPRING OF 2018.
Full Article
Jan 3 (Reuters) - Albireo Pharma Inc ::ALBIREO ANNOUNCES ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS FOR ELOBIXIBAT IN JAPAN.ALBIREO PHARMA INC - ALBIREO SUBSIDIARY ELIGIBLE TO RECEIVE UP TO $60 MILLION UNDER AGREEMENT.ALBIREO PHARMA INC - DECISION ON JAPANESE NEW DRUG APPLICATION FOR ELOBIXIBAT EXPECTED IN FIRST HALF OF 2018.ALBIREO PHARMA -HCR OBTAINS RIGHT TO RECEIVE ROYALTIES, SALES MILESTONES FOR ELOBIXIBAT IN JAPAN THAT MAY BE PAYABLE BY EA PHARMA, UP TO A THRESHOLD.ALBIREO PHARMA INC - ELOBIX HAS RETAINED ITS RIGHT TO RECEIVE A MILESTONE PAYMENT FROM EA PHARMA IF ELOBIXIBAT IS APPROVED BY MHLW.ALBIREO PHARMA INC - IF SPECIFIED THRESHOLD IS REACHED, ELOBIX WILL AGAIN BECOME ELIGIBLE TO RECEIVE ROYALTIES AND SALES MILESTONES FOR ELOBIXIBAT.
Full Article
Nov 14 (Reuters) - Albireo Pharma Inc :Albireo reports third quarter 2017 financial results.Albireo Pharma Inc - decision on potential approval of elobixibat in Japan expected in first half of 2018.Albireo Pharma Inc - revenue totaled $0 for Q3 of 2017 compared with $28,000 for Q3 of 2016.Albireo Pharma Inc - qtrly loss per share $0.73.Albireo Pharma - expects current cash resources will meet operating requirements till end of 2019, assuming receipt of payment from EA Pharma in 2018.
Full Article
Oct 13 (Reuters) - Albireo Pharma Inc :Albireo Pharma Inc files for mixed shelf of up to $125 million - SEC filing .
Full Article